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The term probiotic is utilized to describe useful living microorganisms, 
intended to colonize the large intestine, when consumed in adequate 
amounts, they confer physiological health benefits to the host. In 
the last decade, probiotics have been widely used as a nutritional 
supplement and became a rapidly developing research topic that gai-
ned importance in medicine. Recent clinical trials have found that 
consumption of beneficial bacterial species can manipulate gut flora 
and reduce or prevent the development of certain serious diseases. 
This brief review article is intended to discuss the status of research 
on probiotics, and the value of their consumption in human health.
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Microorganisms may be arbitrarily subdivided for human health into 
two major groups; the pathogenic and the beneficial groups. Microor-
ganisms which benefit humans have been detected for thousands of 
years through the process of using them in food and alcohol fermen-
tations. In the 1900s, a Russian scientist; Élie Metchnikoff (Nobel prize 
winner) linked the consumption of the fermented milk produced by 
the Bulgarians to their long and healthy lives. In 1930, the first clinical 
trial on probiotics outcome in human constipation was completed [1]. 
A Japanese microbiologist, Minoru Shirota in 1930, stated that “many 
diseases could be prevented if human beings have the right combi-
nation of bacteria in their gut”. He has proved successfully by expe-
riment that a beneficial bacterial strain when it was given alive and 
in large quantity can improve intestinal functions and consequently 
the host health. Therefore, he introduced a beneficial bacterial strain 
(Lactobacillus casei strain Shirota) to make a fermented milk drink 
called (Yakult) for consumption as a healthy food. Currently, Yakult 
is a company that have a variety of fermented food products and 
considered a global leader in probiotic market [2]. Received 29-01-2018; Accepted 06-02-2018 
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The World Health Organizations (WHO) and Food 
and Agriculture Organization (FAO) describe pro-
biotics as live microorganisms that have beneficial 
properties for the host when ingested in adequate 
amounts and confer health benefits [2]. FAO/WHO 
expert group also made guidelines for probiotics 
evaluation that contain information needed to verify 
health claims [3]. Nowadays, probiotics are a multi-
billion dollars global industry, and they are used in-
tensively in medical research and treatment [4]. Ne-
vertheless, it is necessary to differentiate between 
the term probiotic, prebiotic, and symbiotic. Pre-
biotic is defined as non-digestible food ingredients 
that affect the host by selectively stimulating the 
growth and activity, or both for a limited number 
of beneficial bacteria in the intestine, whereas the 
mixture of prebiotics and probiotics is referred to as 
symbiotic which is expected to induce synergism in 
the host intestine [3]. WHO and FAO recommend 
that the term "symbiotic" be used only if the net 
health benefit is synergistic [4]. 
The impact of probiotics 
Probiotics are being used to promote several health 
benefits and to relief from many gastrointestinal and 
other diseases. This development has occurred be-
cause probiotics may help in digestion, production 
of beneficial products, stimulating the immune res-
ponse, competing with pathogens and producing 
bactericides during their presence in the host [2, 5]. 
Several intestinal diseases may develop following an 
infection with the enteric pathogens or the over-
growth of one bacterial type. These conditions 
could be controlled or prevented once we control 
the balance of intestinal microflora [6, 7]. Probiotics 
are considered safe because they have been consu-
med for a long time without observing serious side 
effects. The main reason behind their suggested 
safety is the long-term consumption as food before 
they were introduced in medicine [9, 10]. Theoreti-
cally, probiotics could result in some adverse effects; 
including the contribution to antibiotics resistance 
through their ability to transfer resistance genes to 
human intestinal flora, overstimulation of the immu-
ne system and producing adverse metabolic activity 
[10]. The most common microorganisms used in the 
preparation of probiotics are those related to human 
gut flora. These include primarily lactic acid bacteria 
(LAB), Bifidobacteria spp. and Propionibacteria spp. 
These are frequently found in fermented foods, par-
ticularly dairy products. They are quantitatively the 
most essential ingested bacteria. Therefore, most 
studies focused on examining the impact of these 
bacterial groups in probiotics on the gut microbiota 
and the host health [10, 11].
Probiotics mechanisms of actions 
The exact mechanisms by which probiotics exert 
their effects are incompletely understood, some 
mechanisms were proposed; some probiotics ex-
crete lactase that assist in lactose digestion [1]. 
Probiotics can produce lactic acid, benzoic acid 
and hydrogen peroxide altering gut pH and the-
se products have protective effects mostly against 
acid-sensitive bacteria [7]. Probiotics may restore 
the composition of gut microbiome and introduce 
beneficial functions to the gut microbes, resulting 
in amelioration or prevention of gut inflammation 
[12]. Some probiotics create nutrients like provi-
tamins, amino acids, polyamines, antioxidants, 
growth factors and short-chain fatty acids such 
as acetic acid which has antimicrobial function [2, 
7]. Probiotics have some positive effects on both 
specific and non-specific immune response of the 
host by stimulating natural killer cells, monocytes, 
neutrophils and macrophages. This feature could 
be a result of probiotics ability to attach to gut 
epithelium, since attachment of normal and bene-
ficial bacteria was found to prevent the immune 
system over-stimulation which could be brought 
by pathogenic bacteria [7]. Other effects of pro-
biotics include the reduction of the concentration 
of cancer-promoting enzymes [5], prevention and 
alleviation of nonspecific irregular complaints of 
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the gastrointestinal tracts in healthy people [5]. 
Additionally, the possibility of increasing the mu-
cosal immune system by inducing protective cyto-
kines like IL-10 and TGF-beta and immune-modu-
lator cells, while inhibiting the pro-inflammatory 
factors like fecal tumor necrosis factor-alpha which 
mediates intestinal inflammation is suggested [5, 
12]. Also, probiotics can compete with pathogenic 
bacteria by different mechanisms such as compe-
ting with the pathogenic microorganisms for food 
and growth factors, production of antimicrobial 
compounds like cytokines and butyric acid, and 
probiotics aid to increase mucosal renewal and up-
regulation of mucin genes in intestine, this can 
enhance mucous generation which will inhibit the 
adherence and colonization of many foreign mi-
croorganisms [1, 7, 12].
The Benefits of probiotics
In recent years, the natural products have experien-
ced rapid changing and attracted increasing public 
attention for those who are looking for better 
health. There are several reasons behind this health 
care interest, including foundation of many health 
promoting organizations, the wide range of health 
information available on the internet, and the in-
creasing interest in the natural remedies. Probiotics 
consumption is one of the issues that gained increa-
sed interest and ongoing research [13].
Gastrointestinal flora 
The effect of the human flora on gastrointestinal 
tract (GIT) is important for the proper functioning 
of the digestive system and the maintenance of 
good health. It is estimated that the intestinal mi-
croflora consists of 500 -1000 distinctive species of 
bacteria in a single person, approximately their po-
pulation is 10 times the number of the host body 
cells [14]. In addition, the human intestinal tract 
may transiently contain a variety of viruses, yeast 
and parasites [15]. Humans acquire the GIT flora 
during the delivery process as they descend the 
birth canal, then, from their surrounding environ-
ment. Escherichia coli and Streptococcus species 
are the first to colonize the GI tract, later it will be 
followed by Bifidobacteria, Staphylococci, Lactoba-
cilli, Micrococci, and Propionibacteria. Over time, 
microflora shift to anaerobic bacteria types, with 
some interindividual variations. The predominant 
bacteria in the human gut become mostly compo-
sed of Bacteroides, Firmicutes and to less amount 
of Proteobacteria, Actinobacteria, Fusobacteria, 
and Verrucobacteria [14, 15]. It was reported that 
the human GIT maintains a balance between the 
microflora and the immune system, when the in-
testinal microflora is altered or modified. A variety 
of diseases may developed especially diarrhea ini-
tiated by infectious agent, antibiotic-associated or 
traveler’s diarrhea, and constipation, gastroenteri-
tis, inflammatory gut disease, irritable bowel syn-
drome, allergy and some types of intestinal cancers 
[17]. For example, over-growth of one bacterial 
species may alter the digestive function, affecting 
the intestinal immunological function and induce 
disturbance of beneficial characteristics of other 
bacterial species [5]. The following major health 
benefits have been reported to be associated with 
probiotics treatment: 
Diarrhea
Acute diarrheas may range between 2 to 4 days in 
59% of persons, causing the loss of ample amou-
nts of fluids especially in children and the elderly 
patients [18]. The use of probiotics is proved to be 
effective against travelers’ diarrhea and other in-
fectious diarrheas including viral causes e.g. rotavi-
ruses, reducing the frequency and duration. Also, 
probiotics were found to reduce the rates of antibio-
tics associated diarrhea that may occur in about 5 
-25% of adult and young patients during antibiotics 
treatment, but patients must receive high dose of 
probiotics since low doses has no significant effect 
[17-21]. 
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Constipation
Constipation as defined “less than three defecations 
per week and / or hard stool”, it is a common diges-
tive problem among population in all age groups, 
mostly increased in the elderly, due to the changes in 
dietary habits and reduced physical activity. Probio-
tics were found effective in decreasing the severity 
of constipation. Multispecies probiotics have impro-
ved defecation frequency in pregnant women with 
constipation. Lactobacillus reuteri have a remarka-
ble effect against constipation in adults, pregnant 
women and children. Bifidobacterium tetragenous 
was found safe and effective for ameliorating cons-
tipation, even in cancer patients. Therefore, probio-
tics can be effective and safe in the treatment of 
constipation in cancer patients [22, 23, 24]. 
Helicobacter pylori infections
H. pylori is gram-negative spiral bacteria, frequently 
inhabit the human stomach and duodenum. It is 
commonly associated with peptic ulcer disease, 
gastritis, adenocarcinoma and Mucosa-Associated 
Lymphoid Tissue (MALT lymphoma). The standard 
therapy prescribed to eradicate the infection is com-
posed of two antibiotics and a proton pump inhibi-
tor. However, bacterial resistance and drug regimen 
adverse effects compromises their effectiveness, 
reducing H. pylori eradication to less than 55%. 
A recent metanalysis by Haghdoost et al. (2017) 
evaluated the impact of probiotics addition to the 
standard triple therapy in the quest of eradicating 
H. pylori infection, their findings suggested probio-
tics benefit regarding H. pylori eradication in all age 
groups, when added to the standard triple thera-
py [25]. Furthermore, probiotics helped in the triple 
therapy tolerance when minimized nausea, vomi-
ting, diarrhea, and epigastric pain and improving 
patients’ compliance. Lactobacillus salivarius produ-
ces lactic acid which was shown to be effective 
in inhibiting the growth of H. pylori and reducing 
urease activity, an enzyme essential to maintain H. 
pylori colonization and infection. The addition of 
the probiotic adds about 10% efficacy to the era-
dication rate. This is substantial as the prevalence 
of H. Pylori infection is high and can reach around 
40% in the developed countries [25, 26].
Inflammatory bowel diseases (IBD)
Ulcerative colitis and Crohn’s disease are idiopathic 
in etiology, but are associated with abnormal intes-
tinal flora and malfunctioning of mucosal barrier [2]. 
It was found that there is a remarkable decrease in 
the microflora in the IBD patients, mostly, the anti-
inflammatory bacteria Faecalibacterium prausnitzii 
compared with healthy controls. Moreover, it was 
noticed that there was a difference in the microflora 
between the relapses and remissions phases of the 
disease when patients with IBD were treated with 
probiotics [14]. 
Ulcerative colitis (UC)
It is characterized by inflammation and injury of the 
colonic mucosa with relapses and remissions. Ste-
roids are commonly used to induce a remission in 
moderate to severe UC patients. Some patients be-
come resistant to steroids treatment or may develop 
adverse reactions. Probiotics treatment has shown 
to prevent remissions in more than 10% of patients 
during 12 months follow up period compared with 
placebo-treated patients [14, 28]. 
Crohn’s disease (CD)
It is a chronic, lifelong condition. Chronic inflam-
mation may be found in patients’ GIT anywhere 
from the mouth to the anus, but commonly affects 
the end of the small intestine and the beginning 
of the colon. The cause of Crohn’s disease is still 
not well established. However, intestinal immune 
system and bacterial antigens originated from in-
testinal bacterial flora, or infection are incriminated 
to trigger such chronic inflammatory condition [29]. 
Many studies using single bacterial species of pro-
biotics showed no effectiveness in preventing the 
recurrence of CD after surgical intervention, howe-
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ver, one-year consumption had noteworthy results 
of reducing recurrence as well as the pro-inflamma-
tory cytokines, especially when probiotics treatment 
is administered before surgery rather than later [29]. 
Several studies revealed controversial results; two 
studies were conducted using Lactobacillus GG, 
the first one demonstrated a considerable clinical 
improvement in children suffering from active CD, 
while the other study found that the probiotics can-
not prevent its relapse, with no significant statistical 
differences compared with placebo [30]. Whereas, a 
study used Escherichia coli in high dose has repor-
ted a significant effect in the prevention of relapses 
in CD patients, and the use of a mixture of eight 
bacterial strains did not have a significant result over 
placebo after 90 days consumption for the preven-
tion of CD recurrence [30]. 
Lactose intolerance
Lactose intolerance is a clinical ailment that re-
sults from lactose mal-digestion which develops 
following the decreasing lactase enzyme activi-
ty in human intestine, this enzyme is responsible 
for digestion of lactose (disaccharide composed of 
glucose and galactose) which is usually found in 
mammalian milk. Undigested lactose in the large 
intestine will activate the action of microflora to 
facilitate its fermentation, with the production of 
hydrogen, carbon dioxide and organic acids [27]. 
This is clinically manifested as diarrhea, vomiting, 
bloating, abdominal pain, flatulence and cramps. 
The primary intervention against lactose intoleran-
ce is to limit the use of the diary product, hence, 
limiting their benefits, other interventions is to use 
lactase enzyme supplements. The use of probiotics, 
especially lactic acid-producing bacteria is useful to 
metabolize and absorb lactose, and decrease the 
fermentation products due to its ability to produce 
lactase enzyme. The use of Lactobacillus acidophilus 
can also improve lactose intolerance symptoms du-
ring lactose consumption [27, 26]. 
Probiotics and immune system
The use of probiotics enhances the immune system 
by contributing with specific and nonspecific im-
mune responses especially cytokines release, natural 
killer, macrophage activation, increase immunoglo-
bulin levels. This immune reactions occurs without a 
noticeable harmful inflammatory response [31, 32]. 
Lactobacillus and Bifidobacterium species are the 
most known bacteria included in such probiotics. It 
seems that the types and the doses of the bacterial 
strains are significant factors that may influence the 
host immune system [32]. Some Lactobacillus strains 
have shown to affect many aspects of the immune 
system and to suppress the inflammation associated 
with atherosclerosis, whereas, other strains of the 
same species like Lactobacillus species have pro-
atherogenic role [31]. 
Several studies showed that probiotics administe-
red as supplements improved the immune system 
and could be administrated to neonates and the 
elderly. The daily use of the probiotics Lactobacillus 
rhamnosus HN001 and Bifidobacterium lactis by the 
mother before delivery and during lactation showed 
significant increase in neonate cord blood cytokine 
(IFN-γ) as well as in IgA in breast milk [32]. A recent 
study showed a significant increase in phagocytic 
activity of blood leukocytes after three weeks of 
milk probiotics consumption or the consumption 
of probiotics-supplemented milk for nine weeks by 
healthy elderly persons. Also, it showed a significant 
increase of T lymphocytes and Natural Killer [32]. 
The use of probiotics as adjuvants
The use of probiotics to improve the immunity 
after vaccination has been studied and indicated 
meaningful results. A recent review article reported 
by Zimmermann and Curtis found that among 26 
studies involved 3812 participants, and investiga-
ting the effect of 40 different probiotic strains on 
the responses for 17 different vaccines, a beneficial 
effect of probiotics was reported in about half of 
the studies. The evidence for a beneficial effect of 
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probiotics on vaccines responses was strongest for 
oral vaccination, and for parenteral influenza vacci-
nation. Though, substantial variations between stu-
dies in the choice of probiotic, strain, dose, viability, 
purity, and duration and timing of administration 
were reported. Their review suggested that pro-
biotics offer a relatively inexpensive intervention to 
improve vaccine efficacy and duration of protection. 
Future studies must focus on establishing optimal 
strains, doses and timing of administration in rela-
tion to vaccination [33]. 
The use of Lactobacillus casei to motivate the 
immune response for influenza vaccination did not 
show a significant effect through an increase of 
anti-influenza antibody, however, the duration of 
the upper respiratory symptoms was reduced [34]. 
Lactobacillus plantarum had improved the immune 
response to influenza vaccine in elderly by increa-
sing influenza specific IgA and IgG [35]. Lactobaci-
llus paracasei have significantly increased both the 
influenza-specific IgG and IgA after its consumption 
two weeks before and 4 weeks after vaccination, 
while no difference in the cytokines level was detec-
ted [36]. The administration of Lactobacillus rham-
nosus and Lactobacillus paracasei in association of 
live attenuated poliovirus vaccination have shown 
effectiveness by increasing the poliovirus-specific 
IgG and IgA [32]. The combination of probiotic of 
Lactobacillus casei with oral rotavirus vaccine indica-
ted a significant increase in IgM and IgA compared 
with placebo [37]. 
Probiotics for allergy prevention 
The prevalence of allergic diseases and asthma are 
increasing worldwide, particularly in the low- and 
middle-income countries and especially among 
children and young adults [38]. According to the 
WHO, the number of patients having asthma is 
about 300 million and it is expected to increa-
se to 400 million by 2025. Patients with asthma 
and allergic diseases have a low quality of life [38]. 
Some studies suggested that the increased preva-
lence of allergic diseases may be developed due to 
lack of microbial stimuli during infancy and early 
childhood. Children with atopic diseases have di-
fferent commensal bacterial groups in their intes-
tines compared to non-atopic children, and such 
differences are also found between countries with 
high and low incidence of atopic diseases. To date, 
there is no enough evidence was detected that 
probiotics can treat or prevent allergic diseases 
in children [39-40]. The use of probiotics against 
eczema showed some benefit, but this is incom-
pletely understood. A meta-analysis demonstrated 
that the use of probiotics showed efficacy in the 
reduction of eczema occurrence by 21%, but its 
effects was limited to the first two years of life, 
and was lost by four years [3]. A study by Allen, et 
al. (2010) has reported that multi-strains probiotic 
administrated to pregnant women from 36 weeks 
of gestation till six months postpartum significantly 
improved atopic eczema, and sensitivity to cow’s 
milk and egg proteins in the newborn [18]. A re-
cent study of Dennis-wall, et al. (2017) also found 
that the administration of multi-strain probiotics by 
adults has shown improvement in seasonal aller-
gy, particularly the attacks of rhino-conjunctivitis 
and quality of life, the associated mechanism is 
still unclear, though it may be due to probiotics 
ability to increase regulatory T cells and inducing 
tolerance [40]. However, the available evidence 
points that probiotics may have a role in allergy 
preventions though more research is needed to 
clarify this point.
Cancer and probiotics 
Recently, the beneficial use of probiotics against can-
cer has been investigated because of their effects 
on inhibiting the growth of many harmful microor-
ganisms that produce mutagens and carcinogens. A 
recent study by Motevaseli, et al. (2017) has discus-
sed the effects of probiotics on the improvement 
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of the immune system by protection from oxidative 
substance and other health benefits, like reducing 
the development of colorectal cancer (CRC) in ani-
mal models for example. The use of Lactobacillus 
rhamnosus GG as a prophylaxis from CRC was 
found due to the induction of dimethyl hydrazine 
in animal models through different pathways [41, 
42]. It was reported that the intestinal microflora of 
CRC patients were different from controls without 
cancer. The two most common observations were 
the increasing variety of bacterial species and the 
abundance of specific strains like Peptostreptococ-
cus, Selenomonas and Fusobacterium in CRC pa-
tients [43]. A change in the balance of the intestinal 
microflora could be a risk factor for the CRC by 
inhibiting the regulatory role of the normal micro-
bial pattern, this effect may encourage the use of 
probiotics to decrease the severity of the CRC [43]. 
Sadahiro, et al. (2014) compared the use of probio-
tics and antibiotics in the preventions of surgical 
site infection, they found that probiotics did not 
differ from placebo [44], though a study by de An-
drade Calaça, et al. (2017) reported that probiotics 
significantly prevented the infection and improved 
postoperative recovery in CRC patients [45].
Probiotics and vaginal infection
Vaginal infection is a common clinical problem in 
women, especially during the reproductive age. 
Bacterial vaginosis (BV) cause itching, pain and va-
ginal discharge. Treatment failure in BV results in the 
propagation of the aerobic intermediate flora and 
aerobic vaginitis (AV). The reduction of the vaginal 
commensal bacteria particularly Lactobacillus spe-
cies that maintain the vaginal normal low pH pro-
duce bactericidal substances which compete with 
pathogens, and can induce over growth of anae-
robic bacteria resulting in bacterial vaginosis (BV) 
[46]. The standard treatment with antibiotic for BV 
and AV has succeed in about 50%. The oral use 
of probiotic containing three Lactobacillus strains 
for 10 days in association with antibiotic treatment 
for women with BV or AV demonstrated favorable 
effects in the prevention of recurrent symptoms 
in up to 51% compared to placebo [47]. Candida 
species commonly cause vulvovaginal candidiasis 
(VVC) in women, mostly married and pregnant, 
with symptoms profile similar to bacterial vaginitis 
[46]. VVC may be recurrent (rVVC) in up to 50% 
among treated women. In addition, to the recent 
high rates of vaginal candidiasis that demonstra-
tes resistance to the treatment associated with the 
wide use of fluconazole [46]. The long-term use of 
vaginal probiotics capsules containing two Lactoba-
cillus strains with antibiotic administration demons-
trated significant prevention of rVVC for long time 
[47]. A study by Murina, et al. (2014) reported that 
the use of the long term two strains of Lactobacillus 
species as a vaginal slow release tablet has preven-
ted the rVVC in 86% of patients for 10 weeks, 
and has also resulted in the inhibition of the rVVC 
for 7 months after discontinuing the probiotics in 
72.3% of patients [48]. The same phenomena were 
demonstrated by Ho, et al. (2016) in pregnant wo-
men whom were colonized with vaginal and rectal 
Group B Streptococcus, when they were treated 
with two Lactobacillus strains of probiotics, it was 
effective in 40% of women compared to 18% in 
the placebo group [49]. The oral administration of 
multi species probiotics has shown antimicrobial ac-
tivity in vitro against Candida albicans and E. coli 
in pre-menopausal women and the ability of pro-
biotics to prevent uro-genital infections and inhibit 
epithelial cell proliferation by increasing the vagina 
pH after 7 days [50-51]. All these results may en-
courage the production of genetically engineered 
probiotics which could be more efficient to prevent 
bacterial and yeast vaginal infection and might re-
place or reduce the administration of antibiotics in 
future [46].
Other health benefits 
Commensal intestinal bacteria play a role in meta-
bolism of proteins, lipids and carbohydrates. These 
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bacteria ferment non-digestible carbohydrates that 
are not used by the host by production of CO2, H2, 
CH4 and short-chain fatty acids (SCFAs) including 
acetate, propionate and butyrate [52]. Most of the-
se SCFAs are produced in the intestine and then 
absorbed by the host contributing to its energy. All 
data support the fact that SCFAs produced by the 
human gut microbiota are playing important roles 
as substrates for glucose, cholesterol, and lipids 
metabolism. Lactobacilli can produce SCFAs by the 
fermentation of carbohydrates end-products such 
as pyruvate, which is generated during the glyco-
lytic pathway; and by the phosphoketolase route 
in a heterofermenting conditions. Bifidobacteria 
are using the fermentation pathway to produce 
mainly acetate and formate during growth under 
carbohydrates limitation, and acetate and lactate 
when carbohydrates are in excess. A recent study 
of Bermudez-Humaran and Langella has reported 
that genetically modified bacteria such as Bifido-
bacterium longum could produce many different 
effects, specially production of superoxide dismu-
tase or catalase which has shown to cure colitis in 
mice. It is also found that Bifidobacterium species 
have selective migration to anaerobic sites of host 
tissues and can live in the hypoxic environment of 
the tumor [52]. A study by Brown, et al. (2004) 
has also demonstrated that the use of probiotic 
in normal subject can reduce the level of serum 
triglycerides by 27%, and the probiotic compo-
sed of Lactobacilllus reuteri once administration 
in animal model has inhibited effectively hyper-
cholesterolemia [9]. The production of SCFAs by 
these bacteria is potentially an essential regulatory 
effector of epithelial proliferation in the gut [52]. 
Many studies found that probiotics may decrease 
serum lipid level in humans and animal. The use of 
multi-strains probiotic in infant has clearly shown 
increase in SCFA in their fecal samples [53]. It was 
reported that certain strains of Lactobacilli and Bi-
fidobacteria bacteria can produce B-vitamins (B1, 
B2, B12 or B9). Both of these bacterial groups were 
isolated from a variety of sources such as the hu-
man and animals gastrointestinal tract (GIT), dairy 
products, plants, and grains [54]. These vitamins 
are normally stored inside the cells and released by 
direct diffusion, using specific transporters in the 
cell membrane or via cellular lyses inside the GIT 
of the host, making these strains ideal candidates 
for the in-situ delivery of group B vitamins [54], 
like Lactobacillus fermentum (CECT5716) which 
was isolated from the lactating mother milk and 
has shown the ability to produce B2 and B9 in 
vitro [54]. 
Safety 
Probiotics have been described generally safe 
(GRAS) by the US Food and Drug Administration 
(FDA). Their safety in human is established through 
consumption of probiotics in food and dairy pro-
ducts for long time, also, many probiotics bacteria 
species are already colonizing parts of human body 
[55-56]. However, both WHO and FAO stated that 
probiotics may results in several types of adverse 
events at least theoretically [9]. 
Possible side effects
Systemic infections 
There are genuine concerns that the “bacterial” 
probiotics may cause infections like bacteremia, 
sepsis and endocarditis. Doron and Snydman repor-
ted from Finland that despite the increasing pro-
biotics consumption over a decade, Lactobacillus 
bacteremia did not increase [9]. In France, the risk 
of Lactobacillus infection was estimated to be 1 per 
10 million. Moreover, people living with HIV, pre-
mature infants, cancer patients on chemotherapy 
whom were given probiotics did not have any side 
effect [55]. Conversely, Sherid, et al. (2016) reported 
a case of liver abscess and bacteremia caused by 
Lactobacillus in 82-year-old female after using Lac-
tobacillus-contain probiotic, but there was no con-
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firmation if the strain was related to the prescribed 
probiotic or a commensal bacterium [58]. Bactere-
mia with L. rhamnosus GG in an adult patient was 
observed when he received an adjunctive probiotic 
treatment for ulcerative colitis [59]. Again, in a case 
report of Lactobacillus bacteremia in a 69-year-old 
male, there was no evidence of genetic relatedness 
of the used probiotic strain to the bacteremic strain 
as confirmed by three molecular methods [60]. All 
reported studies found rare occurrence of any side 
effects in association with probiotic treatment of 
patients. 
Adverse metabolic activity
Some probiotics stains can produce D-lactate 
which could lead to acidosis. There is also con-
cerns that probiotics may cause intestinal ischemia 
due to increasing demand of oxygen in the gut, 
especially in the critically ill patients with ischemic 
bowel diseases and compromised blood flow to 
the gut mucosa. Minor side effects like nausea, 
flatulence and abdominal cramps were reported, 
but most of the studies did not report any adverse 
reactions. Besides, one meta-analysis showed that 
there was a decrease of adverse events by 18-20% 
in patient who have received probiotics compared 
to control. WHO/FAO recommended to evaluate 
new probiotics strains safety by several methods 
including the presence of antibiotic resistance, he-
molytic activity, ability to produce toxins, meta-
bolic activities like D- lactate production in addi-
tion to consumers surveillance [9]. A recent study 
assessed the safety of Lactobacillus helveticus by 
several methods to assure its use as a probiotic. 
Its whole genome sequencing showed no antibio-
tic resistance gene that could be transferred, and 
there were no virulence factors and only few genes 
could result in adverse metabolite reactions. The 
study has also used rats to conduct acute oral to-
xicity tests, and has shown no mortality or toxicity 
and no significant change in weight, behavior and 
physical activity. The author concluded that their 
results suggested that use of Lactobacillus helve-
ticus strain is safe for human consumption [56]. 
Antibiotic resistance
The administration of probiotics and their potential 
interaction with the human gut bacteria raise con-
cerns about their antibiotic resistance profile and 
ability to transfer antibiotic resistance genes despite 
that not all resistance genes could be transferred 
in the host intestinal flora. Many factors can affect 
this transfer, such as genes persistence in plasmid 
or transposons and chromosomes, in addition, to 
the type of bacterial donors and recipients and the 
selective pressure of antibiotic administration [57]. 
However, the available methods can evaluate anti-
biotics resistance profile for bacteria. Genome se-
quencing could be used to asses both resistance ge-
nes and genes with the potential for adverse events 
[55]. Therefore, it is imperative to have knowledge 
of the probiotic resistance profile before its use with 
antimicrobials. 
Overstimulation of the immune system 
There are no studies that have shown that the con-
sumption of probiotics could lead to autoimmune 
disease in humans, considering their effects on the 
innate immune systems.
Conclusion
Though probiotics have been used for decades, 
but the interest in their utilization as therapeutic, 
adjunctive and prophylactic remedies increased in 
recent years and have shown some benefits in se-
veral infections. Currently, the need arises for well- 
controlled studies on probiotics. Moreover, to study 
specific species, either as solitary or in combination 
in a variety of clinical conditions and demonstrate 
their health-related effects. 
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